Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,981 | 5 | 28.9% |
| Unspecified | $49,934 | 35 | 28.9% |
| Travel and Lodging | $44,063 | 30 | 25.5% |
| Consulting Fee | $26,407 | 15 | 15.3% |
| Food and Beverage | $2,056 | 18 | 1.2% |
| Gift | $475.00 | 1 | 0.3% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $68,003 | 22 | $0 (2019) |
| Novo Nordisk AS | $38,400 | 31 | $0 (2021) |
| Relypsa, Inc. | $21,947 | 27 | $0 (2020) |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | $14,328 | 4 | $0 (2017) |
| Amgen Inc. | $12,784 | 6 | $0 (2020) |
| Vifor (International) Ltd. | $11,105 | 6 | $0 (2020) |
| Fresenius USA Marketing, Inc. | $6,276 | 7 | $0 (2021) |
| Vertex Pharmaceuticals Incorporated | $73.24 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $73.24 | 1 | Vertex Pharmaceuticals Incorporated ($73.24) |
| 2021 | $1,524 | 7 | Novo Nordisk AS ($1,275) |
| 2020 | $15,920 | 12 | Amgen Inc. ($6,193) |
| 2019 | $43,986 | 23 | SANOFI-AVENTIS U.S. LLC ($25,664) |
| 2018 | $50,195 | 35 | Novo Nordisk AS ($32,175) |
| 2017 | $61,218 | 26 | SANOFI-AVENTIS U.S. LLC ($42,339) |
All Payment Transactions
104 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2022 | Vertex Pharmaceuticals Incorporated | — | Food and Beverage | In-kind items and services | $73.24 | General |
| 09/22/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 08/05/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 06/17/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9924-4338 • Category: Diabetes | ||||||
| 04/22/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9924-4338 • Category: Diabetes | ||||||
| 04/22/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 04/20/2021 | Fresenius USA Marketing, Inc. | — | Consulting Fee | Cash or cash equivalent | $249.00 | General |
| 01/21/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $650.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 12/31/2020 | Relypsa, Inc. | Veltassa (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Hyperkalemia | ||||||
| 10/19/2020 | Vifor (International) Ltd. | Veltassa (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Potassium Binder | ||||||
| 10/19/2020 | Relypsa, Inc. | Veltassa (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Hyperkalemia | ||||||
| 09/23/2020 | Novo Nordisk AS | Ozempic (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 06/24/2020 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 06/11/2020 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $525.00 | Research |
| Study: NN9924-4338 • Category: Diabetes | ||||||
| 02/17/2020 | Amgen Inc. | Parsabiv (Drug) | — | In-kind items and services | $6,192.55 | Research |
| Study: Etelcalcetide-induced changes in serum calcium and bone turnover markers and the severity of second • Category: Nephrology | ||||||
| 01/24/2020 | Fresenius USA Marketing, Inc. | — | Travel and Lodging | Cash or cash equivalent | $899.79 | General |
| 01/21/2020 | Fresenius USA Marketing, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 01/21/2020 | Fresenius USA Marketing, Inc. | — | Gift | Cash or cash equivalent | $475.00 | General |
| 01/21/2020 | Fresenius USA Marketing, Inc. | — | Travel and Lodging | Cash or cash equivalent | $402.41 | General |
| 01/21/2020 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $250.00 | General |
| 12/20/2019 | Relypsa, Inc. | Veltassa (Drug) | Travel and Lodging | In-kind items and services | $2,600.00 | General |
| Category: Hyperkalemia | ||||||
| 12/14/2019 | Relypsa, Inc. | Veltassa (Drug) | Travel and Lodging | In-kind items and services | $160.95 | General |
| Category: Hyperkalemia | ||||||
| 12/14/2019 | Relypsa, Inc. | Veltassa (Drug) | Travel and Lodging | In-kind items and services | $27.55 | General |
| Category: Hyperkalemia | ||||||
| 12/13/2019 | Relypsa, Inc. | Veltassa (Drug) | Travel and Lodging | In-kind items and services | $484.31 | General |
| Category: Hyperkalemia | ||||||
| 12/13/2019 | Relypsa, Inc. | Veltassa (Drug) | Travel and Lodging | In-kind items and services | $327.35 | General |
| Category: Hyperkalemia | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9924-4221 | Novo Nordisk AS | $25,650 | 5 |
| Etelcalcetide-induced changes in serum calcium and bone turnover markers and the severity of second | Amgen Inc. | $6,193 | 1 |
| NN9924-4222 | Novo Nordisk AS | $4,050 | 3 |
| PH3 KAI 4169 Secondary HPT OLE | Amgen Inc. | $3,072 | 1 |
| Ph3 KAI 4169 Secondary HPT 1 | Amgen Inc. | $2,064 | 2 |
| NN9924-4309 | Novo Nordisk AS | $1,400 | 6 |
| NN9924-4234 | Novo Nordisk AS | $1,350 | 3 |
| Ph3 Head to Head: Comparison of Cinacalcet vs. AMG 416 in Cinacalcet Naive Subjects | Amgen Inc. | $1,331 | 1 |
| NN9924-4257 | Novo Nordisk AS | $1,125 | 2 |
| NN9924-4280 | Novo Nordisk AS | $1,125 | 3 |
| NN9924-4223 | Novo Nordisk AS | $900.00 | 2 |
| NN9924-4338 | Novo Nordisk AS | $775.00 | 3 |
| NN9924-4224 | Novo Nordisk AS | $450.00 | 2 |
| NN9924-4233 | Novo Nordisk AS | $450.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 19 | 20 | $3,640 | $1,202 |
| 2021 | 1 | 29 | 30 | $5,460 | $2,069 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 19 | 20 | $3,640 | $1,202 | 33.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 29 | 30 | $5,460 | $2,069 | 37.9% |
About Dr. David Bushinsky, MD
Dr. David Bushinsky, MD is a Nephrology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629012265.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Bushinsky, MD has received a total of $172,916 in payments from pharmaceutical and medical device companies, with $73.24 received in 2022. These payments were reported across 104 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($49,981).
As a Medicare-enrolled provider, Bushinsky has provided services to 48 Medicare beneficiaries, totaling 50 services with total Medicare billing of $3,271. Data is available for 2 years (2021–2022), covering 2 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Rochester, NY
- Active Since 06/15/2006
- Last Updated 06/29/2023
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1629012265
Products in Payments
- RENVELA (Drug) $68,003
- Veltassa (Drug) $33,031
- Parsabiv (Biological) $6,467
- Parsabiv (Drug) $6,193
- RYBELSUS (Drug) $2,050
- Ozempic (Drug) $125.00
- Repatha (Biological) $124.71
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Rochester
Neera Dahl, Md, MD
Nephrology — Payments: $116,887
Daniel Gray, Md, MD
Nephrology — Payments: $113,994
Fernando Fervenza, M.d, M.D
Nephrology — Payments: $87,112
Robert Mayo, M.d, M.D
Nephrology — Payments: $64,976
Leslie Wong, Md, MD
Nephrology — Payments: $64,754
John Lieske, M.d, M.D
Nephrology — Payments: $48,304